Xin Tong1, Jennifer L Wiltz1,2, Mary G George1, Erika C Odom1,2, Sallyann M Coleman King1,2, Tiffany Chang1,3, Xiaoping Yin1,3, Robert K Merritt1. 1. Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA (X.T., J.L.W., M.G.G., E.C.O., S.M.C.K., T.C., X.Y., R.K.M.). 2. United States Public Health Service, Atlanta, GA (J.L.W., E.C.O., S.M.C.K.). 3. IHRC, Inc., Atlanta, GA (T.C., X.Y.).
Abstract
BACKGROUND: The clinical benefit of intravenous (IV) alteplase in acute ischemic stroke is time dependent. We assessed the overall temporal changes in door-to-needle (DTN) time and examine the factors associated with DTN time ≤60 and ≤45 minutes. METHODS AND RESULTS: A total of 496 336 acute ischemic stroke admissions were identified in the Paul Coverdell National Acute Stroke Program from 2008 to 2017. We used generalized estimating equations models to examine the factors associated with DTN time ≤60 and ≤45 minutes, and calculated adjusted odds ratios and 95% CI. Between 2008 and 2017, the percentage of acute ischemic stroke patients who received IV alteplase including those transferred, increased from 6.4% to 15.3%. After excluding those who received IV alteplase at an outside hospital, a total of 39 737 (8%) acute ischemic stroke patients received IV alteplase within 4.5 hours of the time the patient last known to be well. Significant increases were seen in DTN time ≤60 minutes (26.4% in 2008 to 66.2% in 2017, P<0.001), as well as DTN time ≤45 minutes (10.7% in 2008 to 40.5% in 2017, P<0.001). Patients aged 55 to 84 years were more likely to receive IV alteplase within 60 minutes, while those aged 55 to 74 years were more likely to receive IV alteplase within 45 minutes, as compared with those aged 18 to 54 years. Arrival by emergency medical service, and patients with severe stroke were more likely to receive IV alteplase within 60 and 45 minutes. Conversely, women, black patients as compared with white, and patients with a medical history of diseases associated with stroke were less likely to receive DTN time ≤60 or 45 minutes. CONCLUSIONS: Rapid improvements in DTN time were observed in the Paul Coverdell National Acute Stroke Program; however, opportunities to reduce disparities remain.
BACKGROUND: The clinical benefit of intravenous (IV) alteplase in acute ischemic stroke is time dependent. We assessed the overall temporal changes in door-to-needle (DTN) time and examine the factors associated with DTN time ≤60 and ≤45 minutes. METHODS AND RESULTS: A total of 496 336 acute ischemic stroke admissions were identified in the Paul Coverdell National Acute Stroke Program from 2008 to 2017. We used generalized estimating equations models to examine the factors associated with DTN time ≤60 and ≤45 minutes, and calculated adjusted odds ratios and 95% CI. Between 2008 and 2017, the percentage of acute ischemic strokepatients who received IV alteplase including those transferred, increased from 6.4% to 15.3%. After excluding those who received IV alteplase at an outside hospital, a total of 39 737 (8%) acute ischemic strokepatients received IV alteplase within 4.5 hours of the time the patient last known to be well. Significant increases were seen in DTN time ≤60 minutes (26.4% in 2008 to 66.2% in 2017, P<0.001), as well as DTN time ≤45 minutes (10.7% in 2008 to 40.5% in 2017, P<0.001). Patients aged 55 to 84 years were more likely to receive IV alteplase within 60 minutes, while those aged 55 to 74 years were more likely to receive IV alteplase within 45 minutes, as compared with those aged 18 to 54 years. Arrival by emergency medical service, and patients with severe stroke were more likely to receive IV alteplase within 60 and 45 minutes. Conversely, women, black patients as compared with white, and patients with a medical history of diseases associated with stroke were less likely to receive DTN time ≤60 or 45 minutes. CONCLUSIONS: Rapid improvements in DTN time were observed in the Paul Coverdell National Acute Stroke Program; however, opportunities to reduce disparities remain.
Authors: Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Adrian F Hernandez; Eric D Peterson; Ralph L Sacco; Lee H Schwamm Journal: Stroke Date: 2011-09-01 Impact factor: 7.914
Authors: Gregg C Fonarow; Xin Zhao; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Ying Xian; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: JAMA Date: 2014 Apr 23-30 Impact factor: 56.272
Authors: Ying Xian; Haolin Xu; Barbara Lytle; Jason Blevins; Eric D Peterson; Adrian F Hernandez; Eric E Smith; Jeffrey L Saver; Steven R Messé; Mary Paulsen; Robert E Suter; Mathew J Reeves; Edward C Jauch; Lee H Schwamm; Gregg C Fonarow Journal: Circ Cardiovasc Qual Outcomes Date: 2017-01
Authors: William J Powers; Alejandro A Rabinstein; Teri Ackerson; Opeolu M Adeoye; Nicholas C Bambakidis; Kyra Becker; José Biller; Michael Brown; Bart M Demaerschalk; Brian Hoh; Edward C Jauch; Chelsea S Kidwell; Thabele M Leslie-Mazwi; Bruce Ovbiagele; Phillip A Scott; Kevin N Sheth; Andrew M Southerland; Deborah V Summers; David L Tirschwell Journal: Stroke Date: 2018-01-24 Impact factor: 7.914
Authors: Gregg C Fonarow; Eric E Smith; Jeffrey L Saver; Mathew J Reeves; Deepak L Bhatt; Maria V Grau-Sepulveda; DaiWai M Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: Circulation Date: 2011-02-10 Impact factor: 29.690
Authors: Edward C Jauch; Jeffrey L Saver; Harold P Adams; Askiel Bruno; J J Buddy Connors; Bart M Demaerschalk; Pooja Khatri; Paul W McMullan; Adnan I Qureshi; Kenneth Rosenfield; Phillip A Scott; Debbie R Summers; David Z Wang; Max Wintermark; Howard Yonas Journal: Stroke Date: 2013-01-31 Impact factor: 7.914
Authors: Mary G George; Xin Tong; Henraya McGruder; Paula Yoon; Wayne Rosamond; Andrea Winquist; Judith Hinchey; Hilary K Wall; Dilip K Pandey Journal: MMWR Surveill Summ Date: 2009-11-06
Authors: Richa Sharma; Kori S Zachrison; Anand Viswanathan; Marcelo Matiello; Juan Estrada; Christopher D Anderson; Mark Etherton; Scott Silverman; Natalia S Rost; Steven K Feske; Lee H Schwamm Journal: Circ Cardiovasc Qual Outcomes Date: 2020-03-04
Authors: Robert Mikulík; Michal Bar; Silvie Bělašková; David Černík; Jan Fiksa; Roman Herzig; René Jura; Lubomír Jurák; Lukáš Klečka; Jiří Neumann; Svatopluk Ostrý; Daniel Šaňák; Petr Ševčík; Ondřej Škoda; Martin Šrámek; Aleš Tomek; Daniel Václavík Journal: J Am Heart Assoc Date: 2022-05-16 Impact factor: 6.106
Authors: Maciej Bladowski; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Anna Sawicz-Bladowska; Adrian Doroszko Journal: Oxid Med Cell Longev Date: 2020-08-28 Impact factor: 6.543